Regencell Bioscience Holdings Limited RGC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.19M | -3.19M | -2.66M | -2.66M | -865.30K |
| Total Depreciation and Amortization | 181.90K | 181.90K | 20.40K | 20.40K | 170.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 258.70K | 258.70K | 1.34M | 1.34M | -19.50K |
| Change in Net Operating Assets | 199.40K | 199.40K | -- | -- | 9.40K |
| Cash from Operations | -2.55M | -2.55M | -1.30M | -1.30M | -704.90K |
| Capital Expenditure | -- | -- | -- | -- | -76.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | 1.25M | 1.25M | 1.29M |
| Cash from Investing | 0.00 | 0.00 | 1.25M | 1.25M | 1.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.36M | 9.36M | -- | -- | -- |
| Repurchase of Common Stock | -889.40K | -889.40K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.47M | 8.47M | -- | -- | -- |
| Foreign Exchange rate Adjustments | -3.40K | -3.40K | 12.80K | 12.80K | -89.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.92M | 5.92M | -31.00K | -31.00K | 421.40K |